Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-05-03

Clinical Trial Update: Pemetrexed Plus Gemcitabine in Renal Cell Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemetrexed plus gemcitabine in renal cell carcinoma was terminated; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alimta (pemetrexed)
  • Gemzar (gemcitabine)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2012-05-03